Melanin-Concentrating Hormone (MCH): Role in REM Sleep and Depression.

Frontiers in neuroscience, 9(DEC)

1662-4548

Torterolo, Pablo
Scorza, Cecilia
Lagos, Patricia

2015

10.3389/fnins.2015.00475

Peer reviewed
Melanin-Concentrating Hormone (MCH): Role in REM Sleep and Depression

Pablo Torterolo 1*, Cecilia Scorza 2, Patricia Lagos 1, Jessika Urbanavicius 2, Luciana Benedetto 1, Claudia Pascovich 1, Ximena López-Hill 2, Michael H. Chase 3 and Jaime M. Monti 4

1 Department of Physiology, School of Medicine, Universidad de la República, Montevideo, Uruguay, 2 Department of Experimental Neuropharmacology, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay, 3 WebSciences International and University of California, Los Angeles School of Medicine, Los Angeles, CA, USA, 4 Department of Pharmacology and Therapeutics, School of Medicine, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay

The melanin-concentrating hormone (MCH) is a peptidergic neuromodulator synthesized by neurons of the lateral sector of the posterior hypothalamus and zona incerta. MCHergic neurons project throughout the central nervous system, including areas such as the dorsal (DR) and median (MR) raphe nuclei, which are involved in the control of sleep and mood. Major Depression (MD) is a prevalent psychiatric disease diagnosed on the basis of symptomatic criteria such as sadness or melancholia, guilt, irritability, and anhedonia. A short REM sleep latency (i.e., the interval between sleep onset and the first REM sleep period), as well as an increase in the duration of REM sleep and the density of rapid-eye movements during this state, are considered important biological markers of depression. The fact that the greatest firing rate of MCHergic neurons occurs during REM sleep and that optogenetic stimulation of these neurons induces sleep, tends to indicate that MCH plays a critical role in the generation and maintenance of sleep, especially REM sleep. In addition, the acute microinjection of MCH into the DR promotes REM sleep, while immunoneutralization of this peptide within the DR decreases the time spent in this state. Moreover, microinjections of MCH into either the DR or MR promote a depressive-like behavior. In the DR, this effect is prevented by the systemic administration of antidepressant drugs (either fluoxetine or nortriptyline) and blocked by the intra-DR microinjection of a specific MCH receptor antagonist. Using electrophysiological and microdialysis techniques we demonstrated also that MCH decreases the activity of serotonergic DR neurons. Therefore, there are substantive experimental data suggesting that the MCHergic system plays a role in the control of REM sleep and, in addition, in the pathophysiology of depression. Consequently, in the present report, we summarize and evaluate the current data and hypotheses related to the role of MCH in REM sleep and MD.

Keywords: peptides, hypothalamus, serotonin, raphe, mood, paradoxical sleep, MCH
INTRODUCTION

The search for new pharmacological strategies to treat psychiatric disorders is a “hot topic” in neuroscience. There is also a large body of evidence suggesting that neuropeptides play a critical role in these pathologies (Kormos and Gaszner, 2013). In addition, neuropeptides are also involved in the control of wakefulness and sleep (Richter et al., 2014). A robust example of the results of translational neuroscience research was the discovery of the neuropeptides hypocretins 1 and 2 (also called orexins); the degeneration of hypocretins-containing neurons produces the sleep pathology called narcolepsy (Mignot, 2011). Hypocretins also play a role in mood disorders (Nollet and Leman, 2013).

Research on the neuropeptide melanin-concentrating hormone (MCH) is currently focused on the study of physiological and translational possibilities of the neuropeptide. In the present report, we review the role of the MCHergic system in the control of REM sleep and the pathophysiology of major depression (MD).

PATHOPHYSIOLOGY OF DEPRESSION: ROLE OF THE SEROTONERGIC SYSTEM

The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) lists several depressive disorders. The common features that characterize them are the presence of sadness, empty or irritable moods, which are accompanied by somatic and cognitive changes that significantly affect an individual’s capacity to function. Major Depressive Disorder or MD is a distinctive condition that is diagnosed based on symptomatic criteria such as sadness or melancholia, guilt, irritability and anhedonia. It is accompanied by several symptoms including insomnia or hypersomnia, fatigue, alterations in body weight, thought and concentration impairments as well as recurrent suicidal thoughts (Fava and Kendler, 2000; American-Psychiatric-Association, 2013). MD is one of the most common psychiatric diseases with a prevalence of 5–12% in men and 10–25% in women, and it is considered to be a principal cause of disability, outnumbered only by cardiovascular diseases (Boyd and Weissman, 1981; Murray and Lopez, 1996, 1997a,b). In addition, a great deal of attention has been paid to MD due to its association with suicide; 15–20% of depressive patients end their lives by suicide (Miret et al., 2013). Affective disorders are also particularly disabling and among the most important contributors to the total burden of disease (Miret et al., 2013).

Several mechanisms have been involved in the neurobiology of depression, ranging from synaptic plasticity to epigenetic, and from postnatal neurogenesis to immunological processes (recently reviewed by Palazidou, 2012; Saveanu and Nemeroff, 2012; Palagini et al., 2013; Willner et al., 2013; Ménard et al., 2015). In the present report, we review the role of MCH in depression with an emphasis on its interaction with the serotonergic system. However, it is important to note that in addition to serotonin, other neurotransmitters such as dopamine, noradrenaline, and glutamate have been involved in the pathophysiology of depression; in fact ketamine, a N-methyl-d-aspartate (NMDA) glutamate receptor antagonist can alleviate depressive symptoms in patients within hours of administration (Saveanu and Nemeroff, 2012; Dutta et al., 2015).

The serotonergic system comprises one of the most widely distributed neurochemical systems in the central nervous system (CNS). The majority of the somata of serotonergic neurons are located within the dorsal raphe nucleus (DR); another important group of serotonergic neurons is located in the median raphe nucleus (MR). Due to its projections throughout the CNS, serotonergic neurons are capable of playing an important role in the regulation of emotional states and in several functions including motor activity and the control of sleep and wakefulness (Monti, 2010a,b; Olivier, 2015).

Numerous studies have shown that the serotonergic system is involved in the pathophysiology of MD. Low levels of serotonin and/or its principal metabolite (5-hydroxy-indole-acetic acid) have been found in the urine and cerebrospinal fluid (CSF) of MD patients (Praag, 1977; van Praag and de Haan, 1979; Young, 1993). In addition, the number of attempted suicides by MD patients and its lethality are correlated with a reduced CSF concentrations of serotonin (Roy et al., 1989; Träskman-Bendz et al., 1992; Nordström et al., 1994; Mann et al., 2001; Kalia, 2005; Berton and Nestler, 2006). Furthermore, abnormalities in serotonergic receptors, serotonin reuptake proteins and other alterations in serotonergic neurotransmission have been related to the susceptibility to commit suicide (Arango et al., 1995; Mann, 1998; Courtet et al., 2005; Hamet and Tremblay, 2005; Bondy et al., 2006). Depressive-suicide patients show significant differences in serotonergic markers in the DR compared to control individuals. Therefore, it has been suggested that disruption of the functioning of serotonergic neurons in the DR underlies MD (Underwood et al., 1999; Arango et al., 2001, 2002; Boldrini et al., 2005; Bach-Mizrachi et al., 2006).

The serotonergic system is also involved in the mechanisms of action of antidepressant drugs. The selective serotonin reuptake inhibitors (SSRI) such as fluoxetine or escitalopram, produce its therapeutic action upon the enhancement of central serotonergic neurotransmission (Keller et al., 1992; Holtzheimer and Nemeroff, 2006). A problem related with antidepressant drugs treatment is the delayed onset of the therapeutic effects, despite the fact that these drugs cause an immediate increase in extracellular levels of monoamines. This fact suggests that the acute biochemical effect does not directly determine the therapeutic effect, which is likely produced by slower neurobiological modulations, such as the desensitization of serotonergic receptors, the modulation of intracellular pathways, gene expression of growth factors such as brain-derived neurotrophic factor (BDNF) and the regulation of postnatal neurogenesis (Palazidou, 2012; Saveanu and Nemeroff, 2012; Willner et al., 2013). In spite of the previous statements, it is important to take into account that a meta-analyses study showed that the placebo effect for antidepressant treatment is exceptionally large, and antidepressant medications have reported only modest benefits over placebo treatment (Kirsch et al., 2008; Kirsch, 2014).
REM SLEEP

Sleep remains one of the great neurobiological mysteries. Humans spend one third of their life sleeping, without awareness of the outside world. However, during dreams, there is bizarre cognitive activity that is disconnected from reality and is ruled by internal stimuli (Pace-Schott, 2005).

In mammals, sleep is comprised of two different behavioral states: slow wave sleep, also called non-REM (NREM) sleep and REM (rapid eyes movements) sleep (Carskadon and Dement, 2005; Brown et al., 2012). Polysomnography is the basic tool to study behavioral states; it consists in the simultaneous recording of the electroencephalogram (EEG), electromyogram (EMG), and eye movements (electrooculogram). During wakefulness, there is an optimal interaction with the environment that enables to carry out different behaviors that optimize survival. An EEG consisting of high frequency rhythms and low amplitude waves characterizes wakefulness. In normal adults, NREM sleep occurs at sleep onset. During this period, there is a marked decrease in the interaction with the environment, the adoption of a suitable position to conserve heat, an increase in the threshold of reaction to external stimuli and a decrease in muscle activity and tone. During NREM sleep, the EEG exhibits low frequency (0.5–4 Hz), high amplitude waves and "sleep spindles." NREM sleep is accompanied by a tonic increase in parasympathetic activity, which results in a decrease in visceral activity (Parmeggiani, 1994). In the deepest stage of NREM sleep, cognitive processes (dreams) are absent or minimal (Pace-Schott, 2005).

During a typical night's sleep in a young adult, REM sleep, which occurs with an ultradian rhythm of approximately 90 min, is always preceded by NREM sleep. During REM sleep the EEG is similar to wakefulness (consequently, this state is also called paradoxical sleep). REM sleep is also characterized by the absence of muscle activity (muscle atonia), rapid eye movements, ponto-geniculo-occipital (PGO) waves, theta waves in the hippocampus electrogram, and phasic changes in autonomic activity (Carskadon and Dement, 2005; Siegel, 2011). The arousal threshold for sound stimulation in humans during tonic REM sleep is similar than NREM sleep stage 2, and increases during phasic REM sleep (when rapid eye movements are present) to the same level as NREM sleep stage 4 (Ermi et al., 2010). Dreams are present mostly during REM sleep (Pace-Schott, 2005).

It is well established that the activating system, which is a neuronal network centered in the mesopontine reticular formation, the postero-lateral hypothalamus and basal forebrain, is critical for generating and maintaining wakefulness (Torterolo and Vanini, 2010). The activating system comprises various neurochemical groups of neurons including glutamatergic, serotonergic, dopaminergic, noradrenergic, histaminergic, cholinergic and hypocretinergic (Torterolo and Vanini, 2010; Monti, 2013). On the other hand, the preoptic area is essential for the generation of NREM sleep, while the thalamus is responsible for the generation of slow waves and sleep spindles (Steriade et al., 1993; Torterolo et al., 2009a; Torterolo and Vanini, 2010; Benedetto et al., 2012).

The neuronal network that is “necessary and sufficient” for the generation of REM sleep is located in the mesopontine reticular formation (Siegel, 2011). Within this region, cholinergic neurons of the latero-dorsal and pedunculo-pontine tegmental nucleus (LDT-PPT) as well as glutamatergic neurons of the nucleus pontis oralis (NPO, that is considered the executive area for REM sleep generation) are active during REM sleep (REM “on,” or wake and REM “on” neurons), whereas noradrenergic neurons of the locus coeruleus (LC) as well as serotonergic neurons of the DR and MR suppress their firing (REM “off” neurons; Monti, 2010b; Siegel, 2011; Brown et al., 2012; Chase, 2013a; Boucetta et al., 2014). Neurons of the ventrolateral periaqueductal gray may also play a role in REM sleep generation (Vanini et al., 2007). Mutual interactive models that include REM “on” and REM “off” neurons have been presented in order to explain the generation of REM sleep (Lu et al., 2006; Luppi et al., 2007; Brown et al., 2012). The mesopontine REM sleep-generating neuronal network is strongly modulated by forebrain sites. This region receives important MCHergic and hypocretinergic projections from the hypothalamus (Torterolo et al., 2009b, 2013).

DEPRESSION AND REM SLEEP

A decrease in the latency to the first episode of REM sleep is a trait of MD, and is considered to be one of the most robust and specific biological markers of this condition (Adrien, 2002; Palagini et al., 2013). Furthermore, MD patients have an increase in the total time spent in REM sleep, in the length of the first episode of REM sleep and in the density of rapid eye movements during this state. The fact that most antidepressant drugs decrease or eliminate REM sleep and that selective REM sleep or total sleep deprivation are effective in the treatment of MD, highlights the relationship between MD and REM sleep (Adrien, 2002; Benca, 2005; Palagini et al., 2013). In relation with preceding concepts, serotonergic neuronal activity in the DR is reduced in animal models of depression, while the firing rate of such DR neurons is exacerbated during total sleep deprivation (which appears to be correlated with its antidepressant effect; Yavari et al., 1993; Gardiner et al., 1997).

One of the most widely used preclinical paradigm for assessing antidepressant activity is the forced swimming test (FST) (Porsolt et al., 1977; Porsolt, 2000). When rodents are placed in an inescapable container of water, they swim or climb more following the systemic administration of antidepressant. Thus, these agents prevent an immobility state called “behavioral despair.” Passive (immobility) or active (swimming and/or climbing) responses should be independent from alterations in locomotive activity that the drug may also induce. Strikingly, 24-h of sleep deprivation in rats results in a decrease in the immobility time, which is consistent with an antidepressant effect (Lopez-Rodriguez et al., 2004). Sleep deprivation also enhances the effect of antidepressant drugs treatment (van Luijtelaar and Coenen, 1985). The antidepressant effect of sleep deprivation has been linked to an increase in serotonergic activity (Lopez-Rodriguez et al., 2004).

In conclusion, it has been proposed that patients with MD have an increased “pressure” to generate REM sleep; in other
words, the generation of REM sleep is abnormally promoted or facilitated in these patients. The relationship between REM sleep and MD depends, at least in part, on the activity of serotonergic neurons of the DR. These neurons are involved both in the generation of REM sleep and in the pathophysiology of MD (Adrien, 2002; Palagini et al., 2013).

ROLE OF THE SEROTONERGIC SYSTEM IN REM SLEEP

Serotonergic neurons of the DR have a slow and regular firing during wakefulness, there is a decrease in their activity during NREM sleep, and an almost complete inactivation during REM sleep (“REM-off” neurons; Monti, 2010b). A decrease in the release of serotonin in brain areas during REM sleep correlates with the electrophysiological data of DR neuronal activity (Portas and McCarley, 1994). GABAergic neurons of the DR are involved in the inhibition of serotonergic neurons during REM sleep, and the consequent promotion of this behavioral state (Nitz and Siegel, 1997; Torterolo et al., 2000; Monti, 2010a). On the other hand, experimental activation of DR serotonergic neurons prevents the generation of REM sleep (Monti, 2010a). Hence, the generation of REM sleep depends on the inactivation of the serotonergic neurons; these neurons are considered “permissive” for the generation of this behavioral state.

THE MELANIN-CONCENTRATING HORMONE

MCH is a 19-aminoacids cyclic peptide, which was initially characterized as a circulating factor that mediated color changes in teleost fishes (Torterolo et al., 2011; Macneil, 2013; Monti et al., 2013). MCH was subsequently identified as a neuromodulator in mammals, including humans (ibid.). MCH is synthesized in neurons whose somata are located in the lateral sector of the posterior hypothalamus, dorsomedial hypothalamus and zona incerta; the location of the MCHergic neurons is shown in a coronal section of the hypothalamus of the cat in Figure 1. These neurons project to different regions of the CNS (Bittencourt et al., 1992; Torterolo et al., 2006, 2009b). A small number of MCHergic neurons have been also identified in the olfactory tubercle and the pontine reticular formation (Bittencourt et al., 1992). In addition, MCHergic neurons are present in the medial preoptic area of lactating rats and in the latero-dorsal tegmental nucleus of female rats (Rondini et al., 2007, 2010). MCH is also present in the gastrointestinal tract and pancreas (Pissios et al., 2007; Kokkotou et al., 2008).

The biological functions of MCH are mediated by two G-protein coupled receptors known as MCHR-1 and MCHR-2. Of note, the MCHR-2 gene is a pseudo-gene in rodents but it is functional in carnivores and primates including humans. It has been determined that MCHR-1 activates Gi and Gq proteins and inhibits Ca^{2+} currents. MCH has mainly an inhibitory role, both at the presynaptic level where it decreases the release of GABA and glutamate, and at the post-synaptic level (Gao, 2009; Macneil, 2013).

MCH Regulates the Energy Homeostasis

The MCHergic system was traditionally related to the control of energy homeostasis; i.e., feeding and metabolic activity (reviewed by Macneil, 2013). In this regard, chronic infusion of a synthetic MCHR-1 receptor agonist induces obesity in mice, which is accompanied by hyperphagia, a reduction in body temperature and stimulation of lipogenic activity in the liver as well as white adipose tissue (ibid.). At the same time, genetically-modified animals with over-expression of MCH are obese, whereas animals lacking MCH are hypophagic and lean. These data suggest that by increasing food intake and promoting anabolism, MCH promotes the conservation of body energy.

The MCHergic System Promotes Sleep

Conservation of energy is one of the main functions of sleep (Siegel, 2005). Since MCHergic neurons are critical in the control of energy homeostasis, it is expected to be involved in sleep regulation. MCH, via regulation of the activating and somnogenic systems, promotes sleep, especially REM sleep (reviewed by Torterolo et al., 2011; Monti et al., 2013; Konadhode et al., 2015).

The arguments that support MCH as a sleep promoter are described below. The main experimental results are summarized in Table 1.

![Figure 1](image-url)
| Site | Main effect | References |
|------|-------------|------------|
| Intracerebroventricular (rat) | Increases REM sleep. Moderate increase in NREM sleep | Verret et al., 2003 |
| Dorsal raphe (rat) | Increases REM sleep. Moderate increase in NREM sleep | Lagos et al., 2009 |
| Locus coeruleus (rat) | Increases REM sleep | Monti et al., 2015 |
| Nucleus pontis oralis (cat) | Increases REM sleep | Lagos et al., 2012 |
| Basal forebrain (rat) | Decreases wakefulness. Increases REM sleep in the first 2-h of the recordings | Benedetto et al., 2013 |
| Ventro-lateral preoptic nucleus (VLPO) (rat) | Increases NREM sleep | |

**MCHR-1 ANTAGONIST MICROINJECTION**

| Systemic (rat) | Decreases REM and NREM sleep. Increases wakefulness | Ahnaou et al., 2008 |

**KNOCK-OUT ANIMALS**

| Prepro-MCH (mice) | Sleep less in basal condition. Decreases REM sleep during fasting more than wild-type controls | Willie et al., 2008 |
| MCHR-1 (mice) | Hypersomniac phenotype both in basal conditions and after total sleep deprivation | Adamantidis et al., 2008 |
| MCHR-1 (mice) | Increases wakefulness and reduces NREM sleep. Restraint stress reduced both NREM and REM sleep more than wild-type controls | Ahnaou et al., 2011 |

**Optogenetic STRATEGY**

| Stimulation of MCHergic neurons (mice) | Increases NREM and REM sleep | Konadhode et al., 2013 |
| Stimulation of MCHergic neurons at the onset of REM sleep (mice) | Increases REM sleep duration | Jego et al., 2013 |
| Stimulation of MCHergic neurons (mice) | Induces transitions from NREM to REM sleep and increases REM sleep time | Tsunematsu et al., 2014 |
| Inhibition of MCHergic neurons at the onset of REM sleep (mice) | Reduces the frequency and amplitude of hippocampal theta rhythm | Jego et al., 2013 |
| Inhibition of MCHergic neurons (mice) | No effect | Tsunematsu et al., 2014 |

**Electrophysiology IN VIVO RECORDINGS**

| Identified MCHergic neurons (rat) | Firing rate: REM >NREM sleep >W | Hassani et al., 2009 |

**In vivo Microdialysis SITE**

| Amygdala (human) | MCH release increases during NREM sleep onset | Blouin et al., 2013 |

**MCHergic Neurons Project to the Activating and Limbic Systems**

Classical studies have linked the postero-lateral hypothalamus, where MCHergic neurons are located, with the control of sleep and wakefulness (Torterolo and Vanini, 2010). These neurons have a close anatomical relationship with hypocretin-containing neurons, whose somata are also located within the postero-lateral hypothalamus and project to comparable brain sites (Torterolo et al., 2006, 2009b, 2013; Torterolo and Chase, 2014). Hypocretinergic neurons are considered part of the activating system, and are essential for the maintenance of wakefulness (Torterolo and Vanini, 2003; Chase, 2013b; Torterolo and Chase, 2014). Hence, it is likely that MCHergic and hypocretinergic neurons interact, in a complementary mode, in order to regulate wakefulness and sleep (Torterolo and Chase, 2014).

MCHergic neurons send dense projections to activating and somnogenic regions (Monti et al., 2013). Using retrograde tracers, we have characterized the MCHergic neuronal projections to the NPO (Torterolo et al., 2009b). There is also a high density of MCHergic fibers in activating regions such as DR and LC (Torterolo et al., 2008; Lagos et al., 2011b; Yoon and Lee, 2013). MCHergic fibers in the DR and their anatomical relation with serotonergic neurons are shown in Figure 2. Regions of the limbic system involved in the control of emotional states including amygdala, nucleus accumbens, septum and hippocampus also receive MCHergic fibers and express MCH receptors (Bittencourt et al., 1992; Hervieu et al., 2000; Chee et al., 2013).

We have also documented that tanyocytes in the DR of the cat exhibit immunoreactivity to MCH (Torterolo et al., 2008). Tanyocytes are specialized cells whose somata lies in the ependymal or sub-ependymal region that present long basal processes that projected deeply into the subventricular parenchyma. These cells absorb substances present in the CSF...
and transport them to the neuronal parenchyma (Rodríguez et al., 2005). These data, together with the presence of MCH in the CSF of the rat, sheep and humans (Peyron et al., 2011; Ungerfeld et al., 2011; Pelluru et al., 2013), suggest that the MCHergic system regulates the activity of the DR through a neurohumoral pathway (by volume conduction through the ventricular system) complementing its regulation via direct neuronal projections (Torero et al., 2008).

A wide distribution of MCHR-1 has been identified in the CNS of the rat, which coincides with the distribution of MCHergic fibers (Lembo et al., 1999; Saito et al., 2001). By a novel approach, utilizing intra-cerebro-ventricular administration of MCH labeled with a fluorescent tag (Rhodamine), Devera et al. (2015) have recently shown in cats and rats that neurons of the DR internalize MCH-rhodamine, indicating that they express receptors for MCH (Figures 3A1,A2). In the cat, there is a particularly high density of neurons with MCH receptors surrounding the basal processes of tanycytes within the DR (Devera et al., 2015; Figures 3B,C). MCHR-1 are present both in serotonergic and non-serotonergic neurons of the DR (Figure 4). Some of the non-serotonergic neurons were demonstrated to be GABAergic (Devera et al., 2015). Recently, MCHR-1 mRNA has been identified in serotonergic neurons of the ventro-medial and lateral wing areas of the DR of mice (Spaethling et al., 2014).

MCHergic Neurons are Active during Sleep

Using the Fos protein as a marker of neuronal activity, it has been shown that MCHergic neurons are active during REM sleep in the rat (Verret et al., 2003). Furthermore, Hassani et al. (2009) have recorded MCHergic neurons in non-anesthetized animals. These neurons have a very low frequency of discharge during wakefulness, their firing rate increases slightly during NREM sleep and reaches the maximum level of activation during REM sleep (Hassani et al., 2009). However, even during this state the average discharge rate was still quiet low (approximately 1 Hz) comparing with other neuronal groups (ibid.).

Quantification of MCH during Wakefulness and Sleep

The concentration of MCH in the CSF of rats increases during the light phase, when the animals are predominantly asleep, while it decreases during the dark period when rats are mainly awake (Pelluru et al., 2013). Utilizing the in vivo microdialysis technique, it has been shown that the release of MCH in the amygdala of patients with treatment-resistant epilepsy is minimal during active wakefulness with social interactions, increases after eating (consummatory behavior), and reaches a maximum level at sleep onset (Blouin et al., 2013).

Studies with Genetically Modified Animals

Studies of preproMCH and MCHR-1 knockout mice indicate that the sleep architecture of these animals is altered. Mice lacking MCH, sleep less than wild-type animals (Willie et al., 2008). Moreover, in response to fasting, MCH deficient mice became hyperactive and show a marked decrease in REM sleep.

A study in MCHR-1 knockout mice showed an unexpected hypersomniac-like phenotype, both in basal conditions and after total sleep deprivation, compared to wild-type mice (Adamantidis et al., 2008). According to the authors, these surprising effects might be produced by compensatory mechanisms that have been identified as potential limitations of the gene-targeting approach. In contrast, Ahnaou et al. (2011) described an increase of wakefulness and a reduction of NREM sleep in MCHR-1 knockout mice, which agrees with the currently proposed role of MCH in the regulation of sleep-wake
FIGURE 4 | MCH-rhodamine is internalized in DR serotonergic neurons. In (A1,B1), the photomicrographs shows that MCH-rhodamine (red) was internalized by DR neurons in the cat. Photomicrographs in (A2,B2) depict neurons with serotonin immunoreactivity (green). Superimposition of both photomicrographs is shown in (A3,B3). It is readily observed that MCH-rhodamine is present in serotonergic (arrows) and non-serotonergic neurons (arrowheads). Calibration bars: 20 µm. Original microphotographs taken from the data set of Devera et al. (2015).

states. Moreover, restraint stress further increases wakefulness and reduces both NREM and REM sleep in these mutant mice (Ahnaou et al., 2011).

Administration of MCH or MCHR-1 Receptor Antagonists

Intracerebroventricular administration of MCH in the rat produces a marked increase in REM sleep and a moderate enhancement in the time spent in NREM sleep (Verret et al., 2003). Furthermore, the systemic administration of MCHR-1 antagonists decreases both REM and NREM sleep and increases wakefulness (Ahnaou et al., 2008).

Microinjection of MCH into the DR of the rat facilitates the generation of REM sleep (Lagos et al., 2009). Conversely, the immunoneutralization of endogenous MCH within the DR (through the microinjection of anti-MCH antibodies) produces the opposite effect (Lagos et al., 2011a). Preliminary studies in cats (where the two types of MCH receptors are active) have also shown that MCH microinjections into the DR produced an increase in REM or NREM sleep depending on the exact location of the microinjection sites (Devera et al., 2007).

MCH also promotes REM sleep when microinjected into either the basal forebrain of the rat or the NPO of the cat, two areas related to the generation of this behavioral state (Torterolo et al., 2009b; Lagos et al., 2012). Noradrenergic “REM-off” neurons of the LC are critically involved in the generation of REM sleep and in the pathophysiology of MD (Itoi and Sugimoto, 2010; Brown et al., 2012). Interestingly, microinjections of MCH into this nucleus also produce a marked increase in REM sleep (Monti et al., 2015). In contrast, the administration of MCH into the ventro-lateral preoptic area (VLPO), a NREM sleep promoting area, induced NREM sleep (Benedetto et al., 2013).

Experimental Activation of MCHergic Neurons Induces Sleep

Recent optogenetic studies have confirmed the role of MCH in sleep generation (Jego et al., 2013; Konadhode et al., 2013; Tsunematsu et al., 2014). Konadhode et al. (2013) inserted the gene for the photosensitive rhodopsine-2 cation channel in MCHergic neurons of mice, and specifically stimulated MCHergic neurons. Stimulation induced a decrease in the latency to sleep, reduced the duration of wakefulness and increased the total time spent in NREM and REM sleep during the night, whereas it increased the depth of sleep during the day (ibid.). The authors hypothesized that MCHergic neurons are able to counteract the actions of the activating systems. Consequently, it was concluded that MCHergic agonists might be useful for the treatment of insomnia.

Jego et al. (2013) found that acute optogenetic activation of MCH neurons at the onset of REM sleep extended the duration of REM sleep episodes. In contrast, their acute optogenetic silencing reduced the frequency and amplitude of the hippocampal theta rhythm during REM sleep without affecting the duration of the episodes.

Tsunematsu et al. (2014) showed that acute optogenetic activation of MCH neurons at 10 Hz induced transitions from NREM to REM sleep and increased REM sleep time. Acute optogenetic silencing of MCHergic neurons had no effect on any vigilance state. On the contrary, temporally-controlled ablation of MCH neurons by cell-specific expression of diphtheria toxin A increased wakefulness and decreased NREM sleep duration without affecting REM sleep (Jego et al., 2013; Konadhode et al., 2013; Tsunematsu et al., 2014). The authors concluded that acute activation of MCHergic neurons is sufficient, but not necessary, to trigger the transition from NREM to REM sleep and that MCHergic neurons also play a role in the initiation and maintenance of NREM sleep.

Effect of MCH on Serotonergic Neurons of the Dorsal Raphe

Utilizing in vivo extracellular recordings, we determined that the intracerebroventricular or juxtacellular application of MCH inhibits the discharge of the majority of DR neurons (Devera et al., 2015); some of these neurons were presumed to be serotonergic, according to their electrophysiological and pharmacological characteristics. Figure 5 presents an example of the inhibitory effect of the juxtacellular application of MCH.
FIGURE 5 | Juxtacellular administration of MCH reduces the activity of DRN neurons. The action potential average, the interval histogram and the autocorrelation histogram of a representative DR neuron are presented in (A). The raw recording and frequency histogram are shown in (B). Note that the application of MCH (indicated by the arrow) produced a decrease in the firing rate. Original Figure taken from the data set of Devera et al. (2015).

ROLE OF THE MCHergic SYSTEM IN THE PATHOPHYSIOLOGY OF DEPRESSION

As mentioned above, the large density of MCHergic fibers in the DR, the expression of MCHR-1 in serotonergic neurons, as well as MCHergic projections toward the limbic system, suggest a relevant role of MCH in the control of emotional states. At the same time, MCH facilitates REM sleep (REM sleep is increased in MD) and stimulates the hypothalamus-pituitary-adrenal axis (which is over-activated in MD). These data also suggest that hyperactivity of the MCHergic system is related to certain aspects of MD. There are several evidences that relate MCH and MD (see below); however, most of the data are from preclinical studies. Hence, it is important to be cautious, because the results from animal models of depression may not correspond with clinical findings (recently reviewed by Belzung, 2014).

Borowsky et al. (2002) demonstrated that the MCHR-1 antagonist, SNAP-7941, possesses antidepressant and anxiolytic effects in animal models of MD (Borowsky et al., 2002). Similar results have been presented by other authors (Shimazaki et al., 2006; David et al., 2007; Chung et al., 2010). In addition, following a 5-week exposure to repeated chronic mild stress (an ethologically relevant animal model of depression), in C57Bl/6J mice there is an increase in the hippocampal gene expression of MCHR-1. This increased gene expression was reversed by chronic fluoxetine treatment (Roy et al., 2007).

The importance of the MCHergic system in MD is emphasized in a recent study which suggests that an increase in the expression of preproMCH and consequent MCH receptor down-regulation could be a biomarker of the severity of depressive disorders (Garcia-Fuster et al., 2012).

Because MCHergic neurons regulate energy homeostasis, it is expected that this function would be altered during MD; in fact, changes in body weight are characteristic of patients with MD (American Psychiatric Association, 2013). At the same time, preclinical studies have demonstrated that MCHR-1 antagonists are not only antidepressants, but also have strong anti-obesity effect (Shimazaki et al., 2006; Chung et al., 2010).

As mentioned before, MCH is expressed in neurons of the medial preoptic nucleus of the female rat, which is a critical area in the control of maternal behavior, but only during the post-partum period (Rondini et al., 2010). Recently, Benedetto et al. (2014) have shown that microinjections of MCH into this preoptic nucleus decrease active maternal behaviors during the early post-partum period. Hence, it would be important to know whether a dysfunction of MCH-containing neurons, which are exclusively present during the post-partum period is related to emotional imbalances that take place in 75–80% of mothers between 3 and 5 days after delivery (Lee, 1998).

MCH and Raphe Nuclei: Role in Depression

In Table 2, we summarized the effects of MCH agents applied into the DR and MR. In direct relation with MD, we explored the role of MCH within the rat DR in the generation of depressive-like behaviors (Lagos et al., 2011b; Urbanavicius et al., 2015a). MCH microinjections into the DR induce
TABLE 2 | MCH and the raphe nuclei.

| Substance | Site  | Strategies                              | Main effect                                                                 | References                  |
|-----------|-------|-----------------------------------------|-----------------------------------------------------------------------------|-----------------------------|
| MCH       | DR    | Microinjection and sleep recording      | Increases REM sleep. Moderate increases in NREM sleep                      | Lagos et al., 2009          |
| Anti-MCH antibody | DR    | Microinjection and sleep recording      | Decreases REM sleep. Increases wakefulness                                   | Lagos et al., 2011a         |
| MCH       | DR    | Microinjection, FST                     | Increases immobility time. This effect is blocked by systemic administration of fluoxetine and nortriptyline | Lagos et al., 2011b; Urbanavicius et al., 2015a |
| Anti-MCH antibody | DR    | Microinjection, FST                     | Decreases immobility time                                                    | Lagos et al., 2011b         |
| MCHR1 antagonist (ATC0175) | DR    | Microinjection, FST                     | Reverts the pro-depressive effect of microinjections of MCH into the DR      | Urbanavicius et al., 2015a  |
| MCH       | MR    | Microinjection, FST                     | Increases immobility time                                                    | López Hill et al., 2013     |
| MCH       | DR    | Unit recording, intraventricular and juxtacellular administration of MCH | Inhibit serotonergic and non-serotonergic neurons                           | Devera et al., 2015         |
| MCH       | DR    | Microdialysis of serotonin, local perfusion of MCH | At low doses decreases serotonin release                                    | Urbanavicius et al., 2013, 2015b |

All the experiments were performed in rats. FST, forced swimming test.

Conclusions and Future Directions

Preclinical studies suggest that the MCHergic system is involved in the control of REM sleep and depression. The role of MCHergic system in the regulation of sleep, especially REM sleep is well-established. In fact, Luppi et al. (2013) introduced a new model of REM sleep in which the MCHergic neurons plays a REM sleep promoting effect. However, the electrophysiological effect of MCH on the mesopontine areas critical for REM sleep generation (according to this model), such as the ventro-lateral periaqueductal gray and the sublaterodorsal nucleus are still to be tested. Another important issue in the research agenda is to know the role of the other neurotransmitters and neuromodulators (such as neuropeptide E-I, neuropeptide G-E, GABA) that are co-localized with MCH (Macneil, 2013).

Our working hypothesis is that an abnormal increase in the activity of MCHergic neurons is involved in the pathophysiology of depression.
of depression. Hence, it would be important to determine whether depressive patients have higher levels of MCH in the CSF compared to normal subjects. In this respect, Schmidt et al. (2015) have shown that MCH serum levels decrease in major depressive disorder following 4 weeks of antidepressant treatment (Schmidt et al., 2015). However, measurements of MCH within the CSF are of rule.

Finally, preclinical studies have demonstrated that MCHR-1 antagonists have an enormous potential as antidepressant drugs (Shimazaki et al., 2006; Chung et al., 2010). Their efficacy, rapid start of action as well as apparent absence of severe adverse events tends to support the proposal.

ACKNOWLEDGMENTS

Supported by the Agencia Nacional de Investigación e Innovación (ANII) Grant FCE-1-2011-1-5997, and Programa de Desarrollo de Ciencias Básicas (PEDECIBA).

REFERENCES

Adamantidis, A., Salvert, D., Goutagny, R., Lakaye, B., Gervasoni, D., Grisar, T., et al. (2008). Sleep architecture of the melanin-concentrating hormone receptor 1-knockout mice. *Eur. J. Neurosci.* 27, 1793–1800. doi: 10.1111/j.1460-9568.2008.06129.x

Adrien, J. (2002). Neurobiological bases for the relation between sleep and depression. *Sleep Med. Rev.* 6, 341–351. doi: 10.1016/S1090-7039(01)90200-X

Ahnaoua, A., Dautzenberg, F. M., Huysmans, H., Steckler, T., and Drinkenburg, W. H. (2011). Contribution of melanin-concentrating hormone (MCH1) receptor to thermoregulation and sleep stabilization: evidence from MCH1 (-/-) mice. *Behav. Brain Res.* 218, 42–50. doi: 10.1016/j.bbr.2010.11.019

Ahnaoua, A., Drinkenburg, W. H., Bouwknecht, J. A., Alizar, J., Steckler, T., and Dautzenberg, F. M. (2008). Blocking melanin-concentrating hormone MCH1 (1) receptor affects rat sleep/wake architecture. *Eur. J. Pharmacol.* 579, 177–188. doi: 10.1016/j.ejphar.2007.10.017

American-Psychiatric-Association (ed.). (2013). *Diagnostic and Statistical Manual of Mental Disorders.* Washington, DC: American Psychiatric Association.

Arango, V., Underwood, M. D., Boldrini, M., Tamir, H., Kassir, S. A., Hsiung, S., et al. (2001). Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainsstem of depressed suicide victims. *Neuropsychopharmacology* 25, 892–903. doi: 10.1006/npsp.2001.40310-4

Arango, V., Underwood, M. D., Gubbi, A. V., and Mann, J. J. (1995). Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. *Brain Res.* 688, 121–133. doi: 10.1016/0006-8993(95)00523-S

Arango, V., Underwood, M. D., and Mann, J. J. (2002). Serotonin brain circuits involved in major depression and suicide. *Prog. Brain Res.* 136, 443–453. doi: 10.1016/S0079-6123(02)36037-0

Bach-Mizrachi, H., Underwood, M. D., Kassir, S. A., Bakalian, M. J., Sible, E., Tamir, H., et al. (2006). Neuronal tryptophan hydroxylase mRNA expression in the human dorsal and median raphe nuclei: major depression and suicide. *Neuropsychopharmacology* 31, 814–824. doi: 10.1038/jn.2002.89

Belzung, C. (2014). Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects? *Neuropsychopharmacology* 39, 1041–1051. doi: 10.1038/npp.2013.342

Bensa, R. M. (2005). "Mood disorders," in *Principles and Practices of Sleep Medicine*, eds M. H. Kryger, T. Roth, and W. C. Dement (Philadelphia: Elsevier-Saunders), 1311–1326.

Benedetto, L., Chase, M., and Torterolo, P. (2012). GABAergic processes within the Median Preoptic Nucleus promote NREM sleep. *Behav. Brain Res.* 232, 60–65. doi: 10.1016/j.bbr.2012.03.033

Benedetto, L., Pereira, M., Ferreira, A., and Torterolo, P. (2014). Melanin-concentrating hormone in the medial preoptic area reduces active components of maternal behavior in rats. *Peptides* 58, 20–25. doi: 10.1016/j.peptides.2014.05.012

Benedetto, L., Rodriguez-Servetti, Z., Lagos, P., D’Almeida, V., Monti, J. M., and Torterolo, P. (2013). Microinjection of melanin concentrating hormone into the lateral preoptic area promotes non-REM sleep in the rat. *Peptides* 39C, 11–15. doi: 10.1016/j.peptides.2012.10.005

Berton, O., and Nestler, E. J. (2006). New approaches to antidepressant drug discovery: beyond monoamines. *Nat. Rev. Neurosci.* 7, 137–151. doi: 10.1038/nrn1846
Devera, A., Lagos, P., Chase, M., and Torterolo, P. (2007). MCH in the nucleus dorsal del rafe: rol en la vigilia y el sueño. Actas Fisiol. 11, 129.

Devera, A., Pacovich, C., Lagos, P., Falconi, A., Sampogna, S., Chase, M. H., et al. (2015). Melanin-concentrating hormone (MCH) modulates the activity of dorsal raphe neurons. Brain Res. 1598, 114–128. doi: 10.1016/j.brainres.2014.12.032

Dutta, A., McKie, S., and Deakin, J. F. (2015). Ketamine and other potential glutamate antidepressants. Psychiatry Res. 225, 1–13. doi: 10.1016/j.psychres.2014.10.028

Ermis, U., Krakow, K., and Voss, U. (2010). Arousal thresholds during human tonic and phasic REM sleep. J. Sleep Res. 19, 400–406. doi: 10.1111/j.1365-2869.2010.00831.x

Fava, M., and Kendler, K. S. (2000). Major depressive disorder. Neuron 28, 335–341. doi: 10.1016/S0896-6771(00)00112-4

Gao, X. B. (2009). Electrophysiological effects of MCH on neurons in the hypothalamus. Peptides 30, 2025–2030. doi: 10.1016/j.peptides.2009.05.006

García-Fuster, M. J., Parks, G. S., Clinton, S. M., Watson, S. J., Akil, H., and Civelli, J. P., Fornal, C. A., and Jacobs, B. L. (1997). Effects of sleep deprivation on the brainstem noradrenergic systems in stress, anxiety and depression. J. Neurosci. 22, 355–361. doi: 10.1176/jn.22.1.355

Gardner, J. P., Fornal, C. A., and Jacobs, B. L. (1997). Sleep deprivation on the melanin-concentrating hormone into the lateral basal forebrain increases REM sleep and reduces wakefulness in the rat. Life Sci. 90, 895–899. doi: 10.1016/S0361-1696(97)00250-5

Georgescu, D., Sears, R. M., Hommel, J. D., Barrot, M., Bolaños, C. A., Marsh, D. J., et al. (2005). The hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced-swim performance. J. Neurosci. 25, 2933–2940. doi: 10.1523/JNEUROSCI.1714-04.2005

Hamet, P., and Tremblay, J. (2005). Genetics and genomics of depression. Metab. Clin. Exp. 54, 10–15. doi: 10.1016/j.metabol.2005.01.006

Hassani, O. K., Lee, M. G., and Jones, B. E. (2009). Melanin-concentrating hormone (MCH) system in an animal model of depression-like behavior. Eur. Neuropsychopharmacol. 22, 607–613. doi: 10.1016/j.eunm.2011.12.001

Hattori, M., Fornal, C. A., and Jacobs, B. L. (1997). Effects of sleep deprivation on serotonergic neuronal activity in the dorsal raphe nucleus of the freely moving cat. Neuropsychopharmacology 17, 72–81. doi: 10.1016/S0893-133X(97)00025-0

Heinemann, M., Ursin, J., Forsberg, G. S., Joutsa, H., and Tähtinen, J. O. (2005). The brainstem noradrenergic systems in stress, anxiety and depression. J. Psychopharmacol. 19, 400–406. doi: 10.1177/026988110505000200

Holtzheimer, P. E. III, and Nemeroff, C. B. (2006). Advances in the treatment of depression. NeuroRx 3, 42–56. doi: 10.1016/j.nurrx.2005.12.007

Hoshi, K., and Sugimoto, N. (2010). The brainstem noradrenergic systems in stress, anxiety and depression. J. Neuroendocrinol. 22, 355–361. doi: 10.1111/j.1365-2826.2010.01988.x

Hervieu, G. I., Cluderay, J. E., Harrison, D., Meakin, J., Maycock, P., Nasir, S., et al. (2000). The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat. Eur. J. Neurosci. 12, 1194–1216. doi: 10.1046/j.1460-9568.2000.00008.x

Holztemper, S., and Nemeroff, C. B. (2006). Advances in the treatment of depression. NeuroRx 3, 42–56. doi: 10.1016/j.nurrx.2005.12.007

Ito, K., and Sugimoto, N. (2010). The brainstem noradrenergic systems in stress, anxiety and depression. J. Neuroendocrinol. 22, 355–361. doi: 10.1111/j.1365-2826.2010.01988.x

Jego, S., Glasgow, S. D., Herrera, C. G., Ekstrand, M., Reed, S. J., Boyce, R., et al. (2013). Optogenetic identification of a rapid eye movement sleep modulatory circuit in the hypothalamus. Nat. Neurosci. 16, 1637–1643. doi: 10.1038/nmn.3522

Kalita, M. (2005). Neurobiological basis of depression: an update. Metab. Clin. Exp. 34, 24–27. doi: 10.1016/j.metabol.2005.01.009

Katái, Z., Adori, C., Kitka, T., Vas, S., Kalmar, L., Kostyalik, D., et al. (2013). Acute escitalopram treatment inhibits REM sleep rebound and activation of MCH-expressing neurons in the lateral hypothalamus after long-term selective REM sleep deprivation. Psychopharmacology (Berl.) 228, 439–449. doi: 10.1007/s00213-013-3046-4

Keller, M. B., Lavori, P. W., Mueller, T. I., Endicott, J., Coryell, W., Hirschfeld, R. M., et al. (1992). Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch. Gen. Psychiatry 49, 809–816. doi: 10.1001/archpsyc.1992.01820100050010

Kim, T. K., Kim, J. E., Park, J. Y., Lee, J. E., Choi, J., Kim, H., et al. (2015). Antidepressant effects of exercise are produced via suppression of hypothecin/orexin and melanin-concentrating hormone in the basolateral amygdala. Neurobiol. Dis. 79, 59–69. doi: 10.1016/j.nbd.2015.04.004

Kirsch, I. (2014). Antidepressants and the Placebo Effect. Z. Psychiatr. 222, 128–134. doi: 10.1027/2151-2604/a000176
Pissios, P., Ayuso-Mateos, J. L., Sanchez-Moreno, J., and Vieta, E. (2013). Depressive disorders and suicide: epidemiology, risk factors, and burden. *NeuropsychoPsychopharmacol. Biol. Psychiatry* 56, 185–188. doi: 10.1016/j.jnppbp.2014.09.003

Monti, J. M., Torterolo, P., and Lagos, P. (2013). Melanin-concentrating hormone control of sleep-wake behavior. *Sleep Med. Rev.* 17, 293–298. doi: 10.1016/j.smrv.2012.10.002

Murray, C. J., and Lopez, A. D. (1997). *The Global Burden of Disease*. Geneva: World Health Organization.

Murray, C. J., and Lopez, A. D. (1997a). Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. *Lancet* 349, 1498–1504. doi: 10.1016/S0140-6736(96)07492-2

Murray, C. J., and Lopez, A. D. (1997b). Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. *Lancet* 349, 1436–1442. doi: 10.1016/S0140-6736(96)07495-8

Nitz, D., and Siegel, J. (1997). GABA release in the dorsal raphe nucleus: role in the control of REM sleep. *Am. J. Physiol.* 273, R451–R455.

Nollet, M., and Leman, S. (2013). Role of orexin in the pathophysiology of depression: potential for pharmacological intervention. *CNS Drugs* 27, 411–422. doi: 10.1007/s00269-013-0064-2

Nordström, P., Samuelsson, M., Asberg, M., Träskman-Bendz, L., Aberg-Wistedt, A., Nordin, C., et al. (1994). CSF 5-HIAA predicts suicide risk after attempted suicide. *Suicide Life Threat. Behav.* 24, 1–9.

Oliver, B. (2015). Serotonin: a never-ending story. *Eur. J. Pharmacol.* 753, 2–18. doi: 10.1016/j.ejphар.2014.10.031

Pace-Schott, E. (2005). “The neurobiology of dreaming,” in *Principles and Practice of Sleep Medicine*, eds M. H. Kryger, T. Roth, and W. C. Dement (Philadelphia: Elsevier-Saunders), 551–564.

Palagini, L., Baglioni, C., Ciapparelli, A., Gemignani, A., and Riemann, D. (2013). REM sleep disregulation in depression: state of the art. *Sleep Med. Rev.* 17, 377–390. doi: 10.1016/j.smrv.2012.11.001

Palazidou, E. (2012). The neurobiology of depression. *Br. Med. Bull.* 101, 127–145. doi: 10.1093/bmb/ldc004

Parmeggiani, P. L. (1994). “The autonomic nervous system in sleep,” in *Principles and Practice of Sleep Medicine*, ed. M. H. Kryger, T. Roth, and W. C. Dement (Philadelphia: Elsevier-Saunders), 194–203.

Pascovich, C., Devera, A., Lagos, P., Costa, A., Falconi, A., and Torterolo, P. (2011). “Melanin-Concentrating Hormone (MCH) decreases presumed serotonin neuronal activity in the dorsal and median raphe nucleus,” in *Proceedings of the Congreso de la Sociedad Argentina de Neurociencias* (Huerta Grande).

Pascovich, C., Rivas, M., Schwartzkopf, N., Deutch, H., Vollono, P., Lagos, P., et al. (2014). “Efecto de la fluoxetina sobre la actividad de neuronas MCHérgicas y no serotoninérgicas del hipotálamo posterolateral,” in *Proceedings of the XV Jornadas de la Sociedad Uruguaya de Biociencias* (Piriapolis).

Portas, C. M., and McCarley, R. W. (1994). Behavioral state-related changes of extracellular serotonin concentration in the dorsal raphe nucleus: a microdialysis study in the freely moving cat. *Brain Res. 648*, 306–312. doi: 10.1016/0006-8993(94)91132-0

Praga, H. M. (1977). The Harold E. Hinwich Memorial Lecture. Significance of biochemical parameters in the diagnosis, treatment, and prevention of depressive disorders. *Biol. Psychiatry* 12, 101–131.

Richter, C., Woods, I. G., and Schier, A. F. (2014). Neuropeptidergic control of sleep and wakefulness. *Annu. Rev. Neurosci.* 37, 503–531. doi: 10.1146/annurev-neuro-062111-150447

Rodríguez, E. M., Blázquez, J. L., Pastor, F. E., Peláez, B., Pena, P., Peruzzo, B., et al. (2005). Hypothalamic tanyctyes: a key component of brain-endocrine interaction. *Int. Rev. Cytol.* 247, 89–164. doi: 10.1016/S0070-7696(05)47003-5

Rondini, T. A., Rodrigues, B. d. E., de Oliveira, A. P., Bittencourt, J. C., and Elias, C. F. (2007). Melanin-concentrating hormone is expressed in the laterodorsal tegmental nucleus only in female rats. *Brain Res. Bull.* 74, 21–28. doi: 10.1016/j.brainresbull.2007.04.006

Rondini, T. A., Donato, J. Jr., Rodrigues Bde, C., Bittencourt, J. C., and Elias, C. F. (2010). Chemical identity and connections of medial preoptic area neurons expressing melanin-concentrating hormone during lactation. *J. Chem. Neuroanat.* 39, 51–62. doi: 10.1016/j.jchemneu.2009.10.005

Roy, A., De Jong, J., and Linnoila, M. (1989). Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study. *Arch. Gen. Psychiatry* 46, 609–612. doi: 10.1001/archpsyc.1989.01810070335005

Roy, M., David, N., Cueva, M., and Giorgetti, M. (2007). A study of the involvement of melanin-concentrating hormone receptor 1 (MCHR1) in murine models of depression. *Biol. Psychiatry* 61, 174–180. doi: 10.1016/j.biopsych.2006.03.076

Roy, M., David, N. K., Danao, J. V., Baribault, H., Tian, H., and Giorgetti, M. (2006). Genetic inactivation of melanin-concentrating hormone receptor subtype 1 (MCHR1) in mice exerts anxiolytic-like behavioral effects. *Neuropsychopharmacology* 31, 112–120. doi: 10.1038/sj.npp.1300805

Saito, Y., Cheng, M., Leslie, F. M., and Civelli, O. (2001). Expression of the melanin-concentrating hormone (MCH) receptor mRNA in the rat brain. *J. Comp. Neurol.* 435, 26–40. doi: 10.1002/cne.1191

Saveanu, R. V., and Nemeroff, C. B. (2012). Etiology of depression: genetic and environmental factors. *Psychiatr. Clin. North Am.* 35, 51–71. doi: 10.1016/j.psc.2011.12.001

Schmidt, F. M., Nowak, C., Kratzsch, J., Sandor, C., Hegel, U., and Schönknecht, P. (2015). Dynamics of melanin-concentrating hormone (MCH) serum levels in major depressive disorder during antidepressant treatment. *J. Affect. Disord.* 180, 207–213. doi: 10.1016/j.jad.2015.03.039

Shimazaki, T., Yoshimizu, T., and Chaki, S. (2006). Melanin-concentrating hormone MCH(1) receptor antagonists: a potential new approach to the treatment of depression and anxiety disorders. *CNS Drugs* 20, 801–811. doi: 10.1007/bf03988425

Siegel, J. M. (2005). Clues to the functions of mammalian sleep. *Nature 437*, 1264–1271. doi: 10.1038/nature04285

Siegel, J. M. (2011). “REM sleep,” in *Principles and Practice of Sleep Medicine*, eds M. H. Kryger, T. Roth, and W. C. Dement (Philadelphia: Elsevier-Saunders), 92–111.

Spachting, J. M., Piel, D., Dudek, H., Buckley, P. T., Morris, J. F., Fisher, S. A., et al. (2014). Serotonergic neuron regulation informed by in vivo single-cell transcriptomics. *FASEB J.* 28, 771–780. doi: 10.1096/fj.13-240267

Steriade, M., McCormick, D. A., and Sejnowski, T. J. (1993). Thalamocortical oscillations in the sleeping and aroused brain. *Science* 262, 679–685. doi: 10.1126/science.8235588

Torterolo, P., Benedetto, L., Lagos, P., Sampogna, S., and Chase, M. H. (2009a). State-dependent pattern of Fos protein expression in regionally-specific sites within the preoptic area of the cat. *Brain Res. 1267*, 44–56. doi: 10.1016/j.brainsres.2009.02.054
Torterolo, P., Yamuy, J., Sampogna, S., Morales, F. R., and Chase, M. H. (2000). Melanin-concentrating hormone (MCH): a new sleep factor? Front. Neurol. 2:14. doi: 10.3389/fneur.2011.00014

Torterolo, P., Lagos, P., Sampogna, S., and Chase, M. H. (2008). Melanin-concentrating hormone (MCH) immunoreactivity in non-neuronal cells within the raphe nuclei and subventricular region of the brainstem of the cat. Brain Res. 1210, 163–178. doi: 10.1016/j.brainres.2008.02.014

Torterolo, P., Sampogna, S., and Chase, M. H. (2009b). MCH-ergic projections to the nucleus pontis oralis participate in the control of active (REM) sleep. Brain Res. 1268, 76–87. doi: 10.1016/j.brainres.2009.02.055

Torterolo, P., Sampogna, S., and Chase, M. H. (2013). Hypocretinergic and non-hypocretinergic projections from the hypothalamus to the REM sleep executive area of the pons. Brain Res. 1491, 68–77. doi: 10.1016/j.brainres.2012.10.050

Torterolo, P., Sampogna, S., Morales, F. R., and Chase, M. H. (2006). MCH-containing neurons in the hypothalamus of the cat: searching for a role in the control of sleep and wakefulness. Brain Res. 1119, 101–114. doi: 10.1016/j.brainres.2006.08.100

Torterolo, P., and Vanini, G. (2010). New concepts in relation to generating and maintaining arousal. Rev. Neurol. 55, 747–758.

Torterolo, P., Yamuy, J., Sampogna, S., Morales, F. R., and Chase, M. H. (2000). GABAergic neurons of the cat dorsal raphe nucleus express c-fos during carbachol-induced active sleep. Brain Res. 884, 68–76. doi: 10.1016/S0006-8993(00)02891-2

Träskman-Bendz, L., Alling, C., Oreland, L., Regnell, G., Vinge, E., and Ohman, R. (1992). Prediction of suicidal behavior from biologic tests. J. Clin. Psychopharmacol. 12, 215–265. doi: 10.1093/clinps/12.3.215

Tsunematsu, T., Ueno, T., Tabuchi, S., Inutoku, A., Tanaka, K. F., Hasuwa, H., et al. (2014). Optogenetic manipulation of activity and temporally controlled cell-specific ablation reveal a role for MCH neurons in sleep/wake regulation. J. Neurosci. 34, 6896–6909. doi: 10.1523/JNEUROSCI.5344-13.2014

Underwood, M. D., Khaibulina, A. A., Ellis, S. P., Moran, A., Rice, P. M., Mann, J. I., et al. (1999). Morphometry of the dorsal raphe nucleus serotonergic neurons in suicide victims. Biol. Psychiatry 46, 473–483. doi: 10.1016/S0006-3223(99)00043-8

Ungerfeld, R., Alzagrayar, S., Quintela, H. G., Lagos, P., Torterolo, P., and Bielli, A. (2011). Melanin concentrating hormone (MCH) in the cerebrospinal fluid of ewes during spontaneous oestrous cycles and ram effect induced follicular phases. Peptides 32, 2511–2513. doi: 10.1016/j.peptides.2011.10.013

Urbanavicius, J., Lagos, P., Torterolo, P., and Scorza, C. (2015b). Melanin-concentrating hormone projections to the dorsal raphe nucleus: an immunofluorescence and in vivo microdialysis study. J. Chem. Neuroanat. (in press).

Urbanavicius, J., Lagos, P., Torterolo, P., and Scorza, C. (2015a). Pro-depressive effect induced by microinjections of MCH into the dorsal raphe: time-course, dose-dependence, effects on anxiety-related behaviors and reversion by nortriptyline. Behav. Pharmacol. 25, 316–324. doi: 10.1097/FBP.0000000000000056

Vanini, G., Torterolo, P., McGregor, R., Chase, M. H., and Morales, F. R. (2007). GABAergic processes in the mesencephalic tegmentum modulate the occurrence of active (rapid eye movement) sleep in guinea pigs. Neuroscience 145, 1157–1167. doi: 10.1016/j.neuroscience.2006.12.051

Verret, L., Goutagny, R., Fort, P., Cagnon, L., Salvert, D., Léger, L., et al. (2003). A role of melanin-concentrating hormone producing neurons in the central regulation of paradoxical sleep. BMC Neurosci. 4:19. doi: 10.1186/1471-2202-4-19

Willie, J. T., Sinton, C. M., Maratos-Flier, E., and Yanagisawa, M. (2008). Abnormal response of melanin-concentrating hormone deficient mice to fasting: hyperactivity and rapid eye movement sleep suppression. Neuroscience 156, 819–829. doi: 10.1016/j.neuroscience.2008.08.048

Willner, P., Scheel-Kruger, J., and Belzung, C. (2013). The neurobiology of depression and antidepressant action. Neurosci. Biobehav. Rev. 37(10 Pt 1), 2331–2371. doi: 10.1016/j.neubiorev.2012.12.007

Yavari, P., Vogel, G. W., and Neill, D. B. (1993). Decreased raphe unit activity in a rat model of endogenous depression. Brain Res. 611, 31–36. doi: 10.1016/0006-8993(93)91773-L

Yoon, Y. S., and Lee, H. S. (2013). Projections from melanin-concentrating hormone (MCH) neurons to the dorsal raphe or the nuclear core of the locus coeruleus in the rat. Brain Res. 1490, 72–82. doi: 10.1016/j.brainres.2012.08.022

Young, S. N. (1993). The use of diet and dietary components in the study of factors controlling affect in humans: a review. J. Psychiatry Neurosci. 18, 235–244.

Conflicts of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.